Third-generation antidepressants: Do they offer advantages over the SSRIs?

CNS Drugs

Volumn 15, Issue 12, 2001, Pages 941-954

  Olver, James S ^a   Burrows, Graham D ^a   Norman, Trevor R ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CIMETIDINE; CLOMIPRAMINE; CLONAZEPAM; DESIPRAMINE; DIAZEPAM; DILTIAZEM; DOSULEPIN; FLUOXETINE; IMIPRAMINE; LORAZEPAM; MIANSERIN; MIRTAZAPINE; NEFAZODONE; NIFEDIPINE; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIAZOLAM; UNINDEXED DRUG; VENLAFAXINE;

CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; HEADACHE; HUMAN; INSOMNIA; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW; SOMNOLENCE; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 0035663882     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200115120-00004     Document Type: Review

References (84)

1. Blockade by newly developed antidepressants of biogenic uptake in the rat brain synaptosomes
2. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: Behavioural and biochemical studies
3. Binding of antidepressants to human brain receptors: Focus on newer generation compounds
4. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers
5. Mirtazapine: A review of its pharmacology and therapeutic potential in the management of major depression
6. A double blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression
7. A comparison of venlafaxine, trazodone, and placebo in major depression
8. Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia
9. A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression
10. A randomized, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression
11. Randomised, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression
12. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety
13. Randomised, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder
14. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia
15. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia
16. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
17. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison
18. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
19. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
20. Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depression
21. Reboxetine versus imipramine in the treatment of elderly patients with major depressive disorders: A double-blind randomized trial
22. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations
23. Reboxetine versus fluoxetine: An overview of efficacy and tolerability
24. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder
25. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale
26. Role of serotonin and noradrenaline in social dysfunction: A review of data on reboxetine and the Social Adaptation Self-Evaluation Scale
27. The impact of antidepressant use on social functioning: Reboxetine versus fluoxetine
28. Reboxetine: Its effects as measured by the Social Adaptation Self-Evaluation Scale
29. Noradrenaline-selective versus serotonin-selective antidepressant therapy: Differential effects on social functioning
30. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression
31. Responders to antidepressant drug treatment: A study comparing nefazodone, imipramine, and placebo in patients with major depression
32. Nefazodone in the treatment of severe, melancholic, and recurrent depression
33. Nefazodone and imipramine in major depression: A placebo-controlled trial
34. A double-blind comparison of nefazodone, imipramine, and placebo in major depression
35. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression
36. Nefazodone versus sertraline in outpatients with major depression: Focus on efficacy, tolerability, and effects on sexual function and satisfaction
37. Org 3770 (mirtazapine) versus trazodone: A placebo controlled trial in depressed elderly patients
38. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients
39. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder
40. A double-blind comparison of ORG 3770, amitriptyline, and placebo in major depression
41. A multicentre, double-blind, amitriptyline-controlled study of mirtazapine in patients with major depression
42. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770
43. Org 3770 versus amitriptyline: A 6-week randomized double blind multicentre trial in hospitalized depressed patients
44. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder
45. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
46. Mirtazapine is more effective than trazodone: A double blind controlled study in hospitalized patients with major depression
47. How recurrent and predictable is depressive illness?
48. Efficacy of venlafaxine and placebo during long-term treatment of depression: A pooled analysis of relapse rates
49. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
50. Long-term treatment of depression with nefazodone
51. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression
52. Mirtazapine versus amitriptyline in the long-term treatment of depression: A double-blind placebo-controlled study
53. Antidepressants: Can we determine how quickly they work? Issues for the literature
54. The new depression scale designed to be sensitive to change
55. Antidepressant drug therapy: The role of the new antidepressants
56. How fast are antidepressants?
57. Early onset of antidepressant action of venlafaxine: Pattern analysis in intent-to-treat patients
58. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia
59. Mirtazapine versus selective serotonin reuptake inhibitors
60. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine
61. Cardiovascular safety in depressed patients: Focus on venlafaxine
62. Venlafaxine: A review of its pharmacology and therapeutic potential in depression
63. Fatal venlafaxine overdose
64. A study involving venlafaxine overdoses: Comparison of fatal and therapeutic concentrations in postmortem specimens
65. Serotonin syndrome due to venlafaxine overdose
66. Cardiovascular and neurological toxicity of venlafaxine
67. Drug-drug interactions involving antidepressants: Focus on venlafaxine
68. Reboxetine: A review of antidepressant tolerability
69. Tolerability and safety of reboxetine
70. Effect of reboxetine on the pharmacokinetics of lorazepam in healthy volunteers
71. Reboxetine: A review of its use in depression
72. Tolerability and safety: Essentials in antidepressant pharmacotherapy
73. Nefazodone-induced liver failure: Report of three cases
74. Toxicities and outcomes associated with nefazodone poisoning: An analysis of 1,338 exposures
75. Drug interactions with newer antidepressants: Role of human cytochromes P450
76. Pharmacokinetic interactions of antidepressants
77. Coadministration of nefazodone and benzodiazepines, III: A pharmacokinetic interaction study with alprazolam
78. Coadministration of nefazodone and benzodiazepines, II: A pharmacokinetic interaction study with triazolam
79. Update in the pharmacotherapy of depression
80. Antidepressant drugs: Disturbing and potentially dangerous adverse effects
81. First report of mirtazapine overdose
82. Safety of mirtazapine in overdose
83. In vitro and in vivo studies on the disposition of mirtazapine in humans
84. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6 and 3A4